Allgenesis announces the appointment of Dr. Sunil Patel as Chief Medical Officer

Allgenesis Receives Notice of Grant for AG-86893 in Korea and Japan for the Treatment of Pterygium
Allgenesis Biotherapeutics and AffaMed Therapeutics Announce License Agreement for AG-73305 in Greater China Region
Show all

Taipei, Taiwan/ July 15th, 2021

Allgenesis Biotherapeutics Inc., a Taiwan based specialty pharmaceutical company focused on developing novel ophthalmologic drugs, is pleased to announce the appointment of Sunil Patel, MD, PhD as Chief Medical Officer.  In this new role, Dr. Patel will provide leadership and direction for Allgenesis’ global clinical development and regulatory initiatives and report to Madhu Cherukury, PhD, DABT, CEO.

Dr. Patel is a world-renowned, board-certified ophthalmologist and has been a practicing Vitreoretinal Surgeon for the past 20+ years in the West Texas area. He is currently the Managing Partner at Ophthalmology Specialist of Texas, PLLC and Abilene Surgery Center; the President of Integrated Clinical Research, LLC; and a Staff Investigator for Strategic Clinical Research Group, LLC.

Dr. Patel has participated as a principal investigator in various retinal clinical trials for leading pharmaceutical companies such as Allergan, Alcon, Boehringer Ingelheim, Genentech-Roche, Graybug, Kodiak, Novartis, Opthea, Chengdu Kanghong, and many others. His area of interests includes the applications of novel molecules in the management of retinal degenerative diseases and innovative surgical therapies for the management of retinal diseases such as wet Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

“As a board-certified ophthalmologist in the retinal field, Dr. Patel’s addition to the senior management team at Allgenesis will provide critical support in advancing our clinical programs,” said Dr. Cherukury. “His clinical expertise as well as his extensive medical and research experience will strengthen our clinical development efforts and support the progress of our pipeline.”

Dr. Patel graduated magna cum laude from UCLA’s Department of Chemistry and Biochemistry. He received his M.D. from the University of Texas Southwestern Medical School, where he was the recipient of the Southwestern Medical Foundation Scholarship, and his Ph.D. from the University of Texas Southwestern Graduate School of Biomedical Sciences. Upon completing an internship in internal medicine at the Presbyterian Hospital of Dallas, Dr. Patel completed his residency in ophthalmology at the Doheny Eye Institute-Los Angeles County Hospital at the University of Southern California. His fellowship training was in medical retina, surgical retina, and uveitis at Los Angeles County Hospital-USC.   

About Allgenesis Biotherapeutics Inc.

Allgenesis is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The company is focused on research and development of novel medicines for the treatment of eye diseases. Current projects in the pipeline include AG-73305, a potential blockbuster drug for the treatment of DME, wAMD, and other retinal diseases, AG-86893 for pterygium, and AG-80308 for Dry Eye Disease.